|Product Name||Anti-SARS-CoV-2 Spike S2 Antibody, 2E5|
|Immunogen||Spike S2 subunit Protein|
|Preparation||Rabbits immunized with spike S2 protein were bled and sera were collected. Antibody is purified from pooled sera by antigen affinity chromatography|
|Applications||Western Blot, ELISA and other platforms|
|Reactivity||SARS CoV-2 Spike S2 protein|
|Purification||Antigen affinity chromatography.|
|Storage conditions||For long term storage, the antibody should be stored at -20℃ and is stable for 12 months from the date of receipt. Avoid repeated freeze-thaw cycles. For short term storage, keep at 4oC for a week should be fine.|
|Application Dilution||1:1,000-1:100,000 (platform dependent, customers have to test the optimal concentration on their own platform)|
SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein(S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) (1). SARS-CoV-2 Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). As with most coronaviruses, proteolytic cleavage of the S protein into two distinct peptides, S1 and S2 subunits, is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (2-4). A metallopeptidase, angiotensin-converting enzyme 2 (ACE-2), has been identified as a functional receptor for SARS-CoV2, similar to SARS-CoV-1, through interaction with a receptor binding domain (RBD) located at the C-terminus of S1 subunit (5, 6). The S2 subunit of SARS-CoV-2 shares 90% and 41% amino acid sequence identity with the S2 subunit of SARS-CoV-1 and MERS, respectively. It has been demonstrated the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (7, 8).
- Rota, P.A. et al. (2003) Science 300:1394.
- Bosch, B.J. et al. (2003). J. Virol. 77:8801.
- Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. USA 106:5871.
- Millet, J.K. and G. R. Whittaker (2015) Virus Res. 202:120.
- Li, W. et al. (2003) Nature 426:450.
- Wong, S.K. et al. (2004) J. Biol. Chem. 279:3197.
- Wang, X. et al. (2020) https://doi.org/10.1038/s41423-020-0424-9.
- Wang, K. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.03.14.988345v.
There are no reviews yet.